Scisparc Ltd (SPRC)

$2.23 +0.10 (4.69%)
Market Cap 1.19M
Revenue (ttm) 1.31M
Net Income (ttm) -6.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -479.39%
Debt to Equity Ratio 0.04
Volume 200,800
Avg Vol 412,724
Day's Range N/A - N/A
Shares Out 535,000.00
Stochastic %K 8%
Beta 0.86
Analysts Strong Buy
Price Target $20.00

Company Profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. It also sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufac...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 7 334 47180
Address:
Tower A, 2nd Floor 20 Raul Wallenberg Street, Tel Aviv, Israel
Hedgieguy75
Hedgieguy75 Sep. 8 at 2:33 PM
$SPRC Bidder is back .. someone loading before the move to $3.25-40
0 · Reply
Tenpincher
Tenpincher Sep. 8 at 2:13 PM
$SPRC
0 · Reply
loweone
loweone Sep. 8 at 1:51 PM
$SPRC Not gonna lie this looks like its ready to run. Possible catalyst approaching on merger deal closing.
0 · Reply
BeauRegard
BeauRegard Sep. 6 at 2:39 PM
$SPRC Saturday hopium: AutoMax Motors LTD 2024 Revenue and Loss: 398m ILS or 108-110m USD with 1% net loss. Reverse Merger terms: SPRC retains majority ownership at 50.01%. AutoMax gets the rest. This essentially means SPRC share count will double less 1 or 2 shares in SPRC favor. AutoMax shares will extinguish, they'll receive 99.99% of current SPRC OS totals, with both combined being the new OS. Current SPRC OS: 1.6m or so with an additional 65k on the table via convertible debentures. New SPRC OS estimate: 3.5-4m. New valuation based on 4m OS: PS Ratio of .5x sales - 50m Market cap - $12/share PS Ratio of .25x sales - 25m Market cap - $6/share $6.50 does fill a gap tho
0 · Reply
i_like_bb_stock
i_like_bb_stock Sep. 5 at 6:50 PM
$PPCB and $SPRC both nearing the highs looking for multi day runs here
0 · Reply
TradeDoc
TradeDoc Sep. 5 at 6:31 PM
$SPRC squeeze, let’s go
0 · Reply
MovingFast77
MovingFast77 Sep. 5 at 6:03 PM
$SPRC Get on the rocket before it takes off
0 · Reply
TradeDoc
TradeDoc Sep. 5 at 6:01 PM
$SPRC moving up!
0 · Reply
BeauRegard
BeauRegard Sep. 5 at 3:38 PM
$SPRC Israeli court approval, which according to what I've found.. end of the Month. But if they release PR announcing court date - could send.
0 · Reply
JayBPee
JayBPee Sep. 5 at 3:26 PM
$SPRC is a shit stock. Turd, the one that sinks. It is a total POS dude. Not spreading anything but my opinion. I hope you make lots of money here dude. I moved on.
2 · Reply
Latest News on SPRC
SciSparc: AutoMax's Shareholders Approve Merger with SciSparc

Aug 28, 2025, 9:24 AM EDT - 11 days ago

SciSparc: AutoMax's Shareholders Approve Merger with SciSparc

SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel

Aug 28, 2025, 6:45 AM EDT - 11 days ago

SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

Aug 7, 2025, 7:32 AM EDT - 4 weeks ago

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

Jul 30, 2025, 4:34 PM EDT - 5 weeks ago

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

Jul 30, 2025, 8:12 AM EDT - 5 weeks ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

Jul 22, 2025, 7:32 AM EDT - 6 weeks ago

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

SciSparc Announces 1-for-21 Reverse Share Split

Jun 24, 2025, 5:03 PM EDT - 2 months ago

SciSparc Announces 1-for-21 Reverse Share Split

SciSparc Announces Publication of Japanese Patent Application

May 27, 2025, 7:32 AM EDT - 3 months ago

SciSparc Announces Publication of Japanese Patent Application

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Apr 25, 2025, 7:59 AM EDT - 4 months ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

CMND

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

Mar 3, 2025, 8:25 AM EST - 6 months ago

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

Feb 27, 2025, 8:45 AM EST - 6 months ago

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

Feb 18, 2025, 7:17 AM EST - 7 months ago

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

Feb 4, 2025, 9:00 AM EST - 7 months ago

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

Jan 15, 2025, 7:34 AM EST - 8 months ago

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

Jan 13, 2025, 8:41 AM EST - 8 months ago

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

Jan 7, 2025, 7:25 AM EST - 8 months ago

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

Jan 6, 2025, 11:04 AM EST - 8 months ago

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Jan 6, 2025, 7:50 AM EST - 8 months ago

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

Dec 31, 2024, 9:24 AM EST - 8 months ago

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

S&P 500 Edges Lower, SciSparc Shares Surge

Dec 26, 2024, 2:36 PM EST - 9 months ago

S&P 500 Edges Lower, SciSparc Shares Surge

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

Dec 26, 2024, 6:46 AM EST - 9 months ago

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

Dec 16, 2024, 7:40 AM EST - 9 months ago

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

Sep 30, 2024, 9:25 AM EDT - 1 year ago

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

Sep 26, 2024, 9:05 AM EDT - 1 year ago

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

Sep 23, 2024, 8:17 AM EDT - 1 year ago

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

Sep 18, 2024, 4:09 PM EDT - 1 year ago

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy

Sep 16, 2024, 4:06 PM EDT - 1 year ago

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy

SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer

Sep 11, 2024, 7:40 AM EDT - 1 year ago

SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

Sep 6, 2024, 7:55 AM EDT - 1 year ago

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination

Aug 29, 2024, 4:25 PM EDT - 1 year ago

SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination

SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million

Aug 28, 2024, 8:55 AM EDT - 1 year ago

SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million

SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome

Aug 23, 2024, 4:09 PM EDT - 1 year ago

SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome

SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board

Aug 22, 2024, 8:12 AM EDT - 1 year ago

SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board

SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment

Aug 19, 2024, 4:11 PM EDT - 1 year ago

SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment

Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy

Aug 19, 2024, 7:51 AM EDT - 1 year ago

Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy

SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million

Aug 16, 2024, 4:30 PM EDT - 1 year ago

SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million

SciSparc Updates Regarding the Status of the AutoMax Merger

Aug 14, 2024, 4:53 PM EDT - 1 year ago

SciSparc Updates Regarding the Status of the AutoMax Merger

SciSparc's Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug

Aug 6, 2024, 8:57 AM EDT - 1 year ago

SciSparc's Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug

SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer

Jul 22, 2024, 8:20 AM EDT - 1 year ago

SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer

SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million

Jul 17, 2024, 7:07 AM EDT - 1 year ago

SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million

SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification

Jul 16, 2024, 11:55 AM EDT - 1 year ago

SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification

SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss

Jul 16, 2024, 6:03 AM EDT - 1 year ago

SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss

SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company

Jul 8, 2024, 8:30 AM EDT - 1 year ago

SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company

SciSparc Secures Strategic Advantage with Grant of European Patent

May 31, 2024, 7:17 AM EDT - 1 year ago

SciSparc Secures Strategic Advantage with Grant of European Patent

Action Alliance Research: Family, Friends Need More Resources and Support to Help Loved Ones Who Are Struggling with Their Mental Health

May 21, 2024, 9:26 AM EDT - 1 year ago

Action Alliance Research: Family, Friends Need More Resources and Support to Help Loved Ones Who Are Struggling with Their Mental Health

SciSparc to Acquire AutoMax

Apr 11, 2024, 8:15 AM EDT - 1 year ago

SciSparc to Acquire AutoMax

SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression

Mar 27, 2024, 8:55 AM EDT - 1 year ago

SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression

SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research

Mar 21, 2024, 8:58 AM EDT - 1 year ago

SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research

SciSparc Granted Another Patent, Strengthening its Core Technology in Canada

Mar 18, 2024, 7:29 AM EDT - 1 year ago

SciSparc Granted Another Patent, Strengthening its Core Technology in Canada

SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial

Mar 14, 2024, 8:49 AM EDT - 1 year ago

SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial

Hedgieguy75
Hedgieguy75 Sep. 8 at 2:33 PM
$SPRC Bidder is back .. someone loading before the move to $3.25-40
0 · Reply
Tenpincher
Tenpincher Sep. 8 at 2:13 PM
$SPRC
0 · Reply
loweone
loweone Sep. 8 at 1:51 PM
$SPRC Not gonna lie this looks like its ready to run. Possible catalyst approaching on merger deal closing.
0 · Reply
BeauRegard
BeauRegard Sep. 6 at 2:39 PM
$SPRC Saturday hopium: AutoMax Motors LTD 2024 Revenue and Loss: 398m ILS or 108-110m USD with 1% net loss. Reverse Merger terms: SPRC retains majority ownership at 50.01%. AutoMax gets the rest. This essentially means SPRC share count will double less 1 or 2 shares in SPRC favor. AutoMax shares will extinguish, they'll receive 99.99% of current SPRC OS totals, with both combined being the new OS. Current SPRC OS: 1.6m or so with an additional 65k on the table via convertible debentures. New SPRC OS estimate: 3.5-4m. New valuation based on 4m OS: PS Ratio of .5x sales - 50m Market cap - $12/share PS Ratio of .25x sales - 25m Market cap - $6/share $6.50 does fill a gap tho
0 · Reply
i_like_bb_stock
i_like_bb_stock Sep. 5 at 6:50 PM
$PPCB and $SPRC both nearing the highs looking for multi day runs here
0 · Reply
TradeDoc
TradeDoc Sep. 5 at 6:31 PM
$SPRC squeeze, let’s go
0 · Reply
MovingFast77
MovingFast77 Sep. 5 at 6:03 PM
$SPRC Get on the rocket before it takes off
0 · Reply
TradeDoc
TradeDoc Sep. 5 at 6:01 PM
$SPRC moving up!
0 · Reply
BeauRegard
BeauRegard Sep. 5 at 3:38 PM
$SPRC Israeli court approval, which according to what I've found.. end of the Month. But if they release PR announcing court date - could send.
0 · Reply
JayBPee
JayBPee Sep. 5 at 3:26 PM
$SPRC is a shit stock. Turd, the one that sinks. It is a total POS dude. Not spreading anything but my opinion. I hope you make lots of money here dude. I moved on.
2 · Reply
Tartufo
Tartufo Sep. 5 at 3:01 PM
$SPRC
0 · Reply
SCSteveAustin
SCSteveAustin Sep. 5 at 12:05 PM
$SPRC. Probably gonna see 1.93-1.95 today, keeping it just above the -10% threshold for ssr..... There's been a 8-9% drop every day. Trade accordingly.
1 · Reply
JayBPee
JayBPee Sep. 5 at 7:40 AM
$SPRC Just checking in on this POS. The big pump and dump screwed over so many here. Hitting new lows I see. This crap is going to trade under a dollar before the end of the month (IMO).
1 · Reply
JayBPee
JayBPee Sep. 5 at 7:39 AM
$SPRC
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 4 at 11:38 PM
$SPRC need u 4 tomo*
0 · Reply
Tartufo
Tartufo Sep. 4 at 5:26 PM
$SPRC
0 · Reply
Alwaysloser
Alwaysloser Sep. 4 at 3:35 PM
$SPRC
0 · Reply
BeauRegard
BeauRegard Sep. 4 at 2:54 PM
$SPRC They are also receiving $700K cash + 40% $NITO stake in exchange for MitoCareX
0 · Reply
Alwaysloser
Alwaysloser Sep. 4 at 2:07 PM
$SPRC
0 · Reply
MovingFast77
MovingFast77 Sep. 4 at 12:19 PM
$SPRC Just a matter of time until it just takes off easy 400 to 500% gain
0 · Reply
BeauRegard
BeauRegard Sep. 4 at 3:49 AM
$SPRC you did this. You made me deep dive. Now I must share: It looks like post merger OS will be about 3.5m - with SPRC having majority by .01%. Automax reports $100M USD in annual revenues - but essentially break even net profit numbers. It's still undervalued at .04x sales for market cap. .25x sales is probably higher end of where this should go. .15-.2x sales is realistic. At 3.5m OS and .2x 100m USD revenue or 20m market cap.. $5-6+/share. Should see 3.50-4 minimum.
1 · Reply
BeauRegard
BeauRegard Sep. 4 at 1:21 AM
$SPRC bless your heart
1 · Reply